These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36880401)

  • 1. Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function.
    Laudette M; Lindbom M; Arif M; Cinato M; Ruiz M; Doran S; Miljanovic A; Rutberg M; Andersson L; Klevstig M; Henricsson M; Bergh PO; Bollano E; Aung N; Gustav Smith J; Pilon M; Hyötyläinen T; Orešič M; Perkins R; Mardinoglu A; Levin MC; Borén J
    Cardiovasc Res; 2023 Jul; 119(7):1537-1552. PubMed ID: 36880401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine effects of PCSK9 on cardiomyocytes.
    Wolf A; Kutsche HS; Schreckenberg R; Weber M; Li L; Rohrbach S; Schulz R; Schlüter KD
    Basic Res Cardiol; 2020 Nov; 115(6):65. PubMed ID: 33169229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
    Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
    Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way.
    Schlüter KD; Wolf A; Weber M; Schreckenberg R; Schulz R
    Basic Res Cardiol; 2017 Sep; 112(6):63. PubMed ID: 28913715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy.
    Ding Z; Wang X; Liu S; Shahanawaz J; Theus S; Fan Y; Deng X; Zhou S; Mehta JL
    Cardiovasc Res; 2018 Nov; 114(13):1738-1751. PubMed ID: 29800228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
    Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
    Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice.
    Garçon D; Moreau F; Ayer A; Dijk W; Prieur X; Arnaud L; Roubtsova A; Seidah N; Prat A; Cariou B; Le May C
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2084-2094. PubMed ID: 32673528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
    Chen PW; Tseng SY; Chang HY; Lee CH; Chao TH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-hematopoietic deficiency of proprotein convertase subtilisin/kexin type 9 deficiency leads to more severe anemia in a murine model of sickle cell disease.
    Venugopal J; Wang J; Guo C; Lu H; Chen YE; Eitzman DT
    Sci Rep; 2020 Oct; 10(1):16514. PubMed ID: 33020528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
    Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
    J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells.
    Ali A; Unnikannan H; Shafarin J; Bajbouj K; Taneera J; Muhammad JS; Hasan H; Salehi A; Awadallah S; Hamad M
    Endocrine; 2022 Jun; 76(3):543-557. PubMed ID: 35237909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.